Showing 61 - 80 results of 30,126 for search '(( significant ((we decrease) OR (may increase)) ) OR ( significant decrease decrease ))', query time: 0.56s Refine Results
  1. 61
  2. 62
  3. 63

    Table 3_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.docx by Linda S. Barter (21466916)

    Published 2025
    “…Plasma ketamine concentrations between 1 and 4 μg mL<sup>−1</sup> may elicit benefit with minimal adverse effects.…”
  4. 64

    Image 2_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.jpeg by Linda S. Barter (21466916)

    Published 2025
    “…Plasma ketamine concentrations between 1 and 4 μg mL<sup>−1</sup> may elicit benefit with minimal adverse effects.…”
  5. 65

    Image 1_Increasing plasma ketamine concentrations decrease the minimum alveolar concentration of isoflurane in rabbits.jpeg by Linda S. Barter (21466916)

    Published 2025
    “…Plasma ketamine concentrations between 1 and 4 μg mL<sup>−1</sup> may elicit benefit with minimal adverse effects.…”
  6. 66
  7. 67

    Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease). by Mobina Faqani (22783963)

    Published 2025
    “…<p>Summary of the effect of MPDD on ART and TIBL across all participants, and also participants categorized by driving styles (“NS” (no significant), “+” (significant increase), and “-” (significant decrease).…”
  8. 68
  9. 69
  10. 70
  11. 71

    Table_1_FMT intervention decreases urine 5-HIAA levels: a randomized double-blind controlled study.DOCX by Lihong Wang (14991)

    Published 2024
    “…However, in the placebo group, GSRS, CARS, and SRS scores showed no significant changes, while ABC scores decreased from 72 to 58.75 (p = 0.034). …”
  12. 72

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  13. 73

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  14. 74

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
  15. 75
  16. 76
  17. 77
  18. 78

    HFD decreases intermediate-term memory. by Tong Yue (6033305)

    Published 2025
    “…(C) Food intake was not significantly different between ND- and HFD-fed flies during the 1 hour. …”
  19. 79
  20. 80